StockNews.com Upgrades LivaNova (NASDAQ:LIVN) to "Strong-Buy"

LivaNova (NASDAQ:LIVN - Get Free Report) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Tuesday.

A number of other research firms also recently issued reports on LIVN. Robert W. Baird lifted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Needham & Company LLC reiterated a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a research report on Monday, November 25th. Baird R W raised shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. Mizuho lowered their price objective on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 target price on the stock. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, LivaNova presently has a consensus rating of "Buy" and a consensus target price of $69.17.

LivaNova Stock Performance

Shares of LIVN traded down $0.21 during trading hours on Tuesday, hitting $49.94. The company's stock had a trading volume of 542,908 shares, compared to its average volume of 609,421. The business has a 50 day simple moving average of $51.88 and a two-hundred day simple moving average of $51.27. The company has a market cap of $2.71 billion, a price-to-earnings ratio of 118.90 and a beta of 0.98. LivaNova has a 52-week low of $43.15 and a 52-week high of $64.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the business's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares of the company's stock, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On LivaNova

A number of large investors have recently bought and sold shares of the business. Fifth Third Bancorp grew its stake in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company's stock valued at $37,000 after acquiring an additional 332 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of LivaNova during the 2nd quarter worth about $88,000. Central Pacific Bank Trust Division purchased a new stake in LivaNova in the 3rd quarter valued at $178,000. TradeLink Capital LLC acquired a new position in LivaNova during the 2nd quarter worth approximately $208,000. Finally, Captrust Financial Advisors acquired a new stake in shares of LivaNova during the 3rd quarter valued at approximately $217,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.